Perioperative Treatment with Rivaroxaban and Dabigatran on Changes of Coagulation and Platelet Activation Biomarkers following Left Atrial Appendage Closure
Table 3
Logistic proportional hazard regression analyses for elevated D-dimer.
Variables
Univariate analysis
Multivariate analysis
OR (95% CI)
value
OR (95% CI)
value
Age
1.073 (1.020-1.129)
0.007
1.068 (0.991-1.150)
0.084
Gender (male)
0.542 (0.227-1.294)
0.168
BMI (kg/m2)
1.138 (0.930-1.394)
0.210
CHA2DS2-VASc score
1.176 (0.830-1.665)
0.362
Hypertension
3.873 (0.849-17.667)
0.080
6.739 (0.727-62.444)
0.093
Diabetes mellitus
1.021 (0.420-2.480)
0.964
Hyperlipidemia
1.182 (0.387-3.612)
0.769
Stroke
0.953 (0.385-2.362)
0.917
Anticoagulation protocols (rivaroxaban vs. dabigatran)
3.632 (1.160-11.364)
0.027
0.023 (0.245-4.270)
0.975
Closure size
0.881 (0.689-1.127)
0.313
LVDD
1.041 (0.969-1.118)
0.271
LVDS
1.041 (0.963-1.125)
0.310
LVEF
0.961 (0.905-1.019)
0.184
hs-CRP
1.164 (1.053-1.287)
0.003
1.154 (1.036-1.286)
0.009
Coagulation and platelet activation biomarkers
TAT
LA
1.015 (0.993-1.037)
0.178
LAA
1.007 (0.982-1.034)
0.583
Vein
0.993 (0.962-1.026)
0.677
sP-selectin
LA
1.000 (1.000-1.001)
0.038
1.001 (1.000-1.001)
0.071
LAA
1.000 (1.000-1.001)
0.277
Vein
1.000 (1.000-1.000)
0.954
vWF
LA
1.002 (0.998-1.005)
0.397
LAA
1.001 (0.997-1.006)
0.555
Vein
1.000 (0.997-1.004)
0.933
CD40L
LA
1.000 (0.997-1.003)
0.928
LAA
1.002 (1.000-1.005)
0.072
1.004 (1.000-1.007)
0.049
Vein
1.002 (0.998-1.006)
0.271
The hazard ratio (HR) and the 95% confidence interval (CI) were calculated using univariate Cox regression, and variables with a statistical significance of were entered into the multivariate stepwise Cox proportional hazard regression model. BMI: body mass index; sCr: serum creatinine; RAASi: renin angiotensin aldosterone system inhibitor; LVDD; left ventricular end diastolic dimension; LVDS: left ventricular end systolic diameter; LVEF: left ventricular ejection fraction; hs-CRP: high-sensitivity C-reactive protein.
